News

Theranos making a big comeback with $100 million rebound

Theranos

Theranos is gearing up for its rebound.

The embattled blood-testing startup told investors on Friday that it had raised $100 million in a secured debt financing transaction from Fortress Investment Group. The financing is subject to product and operational milestones, and includes warrants for 4% of the company equity. Fortress was acquired by SoftBank earlier this year.

“Based on our present projections, we believe we will have sufficient liquidity through 2018, by which point we hope to have secured regulatory approval for miniLab testing for the Zika virus and begun submissions for additional assays,” Theranos CEO Elizabeth Holmes wrote in the investor letter reviewed by Business Insider.

It’s the first time the company’s raised a funding round since 2015, the year it started facing questions about the accuracy of its tests. After the last funding round, the company was valued at $9 billion.

Theranos has been under fire since October 2015 after the Journal published an investigation that questioned the accuracy of its blood test. Eventually, one of the company’s lab-testing locations was shut down, and Holmes was originally barred for two years from running a clinical lab. The company later settled with CMS, the government agency responsible for regulating blood-testing labs, by agreeing to not own or operate a clinical lab within the next two years. Theranos said in the letter its continuing to cooperate with the SEC and DOJ in their respective investigations.

The letter outlined the quality, regulatory, and structural changes Theranos has taken in the past year, including consolidating its offices into its Newark, California manufacturing space, adding an anonymous hotline for employees, and getting certain manufacturing licenses. The company has also posted its scientific publications and presentations, an area that has been less transparent for the company in the past.

Holmes also gave investors a timeline of where the company’s headed over the next few years.

  • In the next 18-24 months, Theranos hopes to launch its Zika virus test, and work toward regulatory approval for some infectious disease testing.
  • After that, the company hopes to expand into more routine lab testing.
  • Then, some day, the hope is to have “tailored personal sensing systems,” based on Theranos patents that could be anything from sensors, patches, or testing a patient might be able to do at home.

“We do not underestimate the work ahead,” Holmes wrote. “The Fortress transaction gives us an opportunity to realize product milestones, resolve remaining legal issues and position Theranos for additional financing events down the road. We have a window that requires planning, preparation, and execution.”

Leave a Comment